The FDA sent 30 warning letters to GLP-1 compounders on February 20, 2026, flagging violations including claims of "same active ingredients" as brand-name drugs, language implying therapeutic equivalence, and statements implying FDA approval of compounded products
Nishida Y, Kettlun C, Ostermann L, Kadia T, Andreeff M , Vega F
9 A significant number of WLs, 58 letters, were issued to online telehealth platforms selling compounded products
Several peptides with strong physiological phenotypes were identified before their receptors were cloned or fully characterized, limiting structureactivity relationship studies and medicinal chemistry optimization
Our commitment to transparent service means youll always understand the rationale behind your treatment plan and any dosage adjustments